iTeos will receive $35m from GSK as the first patient is dosed in the Phase III ...
The Susvimo eye implant is filled with Lucentis, which delivers the therapy cont...
SciRhom has secured €63m ($70m) in a Series A funding round to develop iRhom2-ta...
Taiho has exercised an option for an exclusive licence for Arcus Biosciences’ qu...
Ligand Pharmaceuticals has announced a definitive agreement for the acquisition ...
Moderna and Mitsubishi Tanabe have entered into a collaboration to jointly promo...
Morphic’s lead asset MORF-057 is being investigated in three IBD clinical trials...
Dalfampridine IR is under clinical development by Solaxa and currently in Phase ...
AZD-2389 is under clinical development by AstraZeneca and currently in Phase I f...
NN-6561 is under clinical development by Novo Nordisk and currently in Phase I f...
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Ph...
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Ph...
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Ph...
BNT-325 is under clinical development by Duality Biologics (Shanghai) and curren...
CAN-3110 is under clinical development by Candel Therapeutics and currently in P...
ICTCAR-028 is under clinical development by Innovative Cellular Therapeutics and...
